Analytical Data
-
Gene name
SLC15A1
- Application
-
Alternative Names
PEPT1
-
Species
Human
-
Source
HEK293
-
Tag
N-StrepⅡ;C-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P46059
-
Expression Region
G2-M708
-
Protein Length
Partial
-
Molecular Weight
82.2 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SLC15A1, also known as the solute carrier family 15 member 1, is a major transporter identified in humans that plays a critical role in the absorption of oligopeptides and the subsequent transport of dipeptides and other small peptides across the intestinal epithelial barrier. Its function is particularly important for nutrient uptake and has implications for overall health and metabolic processes. Research into the recombinant form of SLC15A1 has gained momentum due to its potential applications in drug delivery systems and understanding the molecular mechanisms of peptide transport. Given that SLC15A1 is involved in the pharmacokinetics of various pharmaceutical compounds, elucidating its structure and function through recombinant protein studies can facilitate the development of targeted therapies and improve the bioavailability of peptide-based drugs. Moreover, mutations or dysfunctions within the SLC15A1 gene have been implicated in various diseases, including inflammatory bowel disease and certain metabolic disorders, highlighting the need for advanced studies. Recombinant SLC15A1 can serve as a valuable tool for exploring protein interactions, substrate specificities, and potential inhibitors, thereby providing insights that may lead to therapeutic innovations. As such, the study of SLC15A1 recombinant protein offers significant promise in enhancing our understanding of peptide transport mechanisms and developing novel strategies for addressing related health issues.
